Side-by-side comparison of AI visibility scores, market position, and capabilities
Travel airport transfer marketplace and API for OTAs and hotels; embedding ground transportation bookings into travel checkout flows backed by YC and Goodwater Capital.
Shuttle Central is a travel transportation marketplace and API platform enabling travel companies, OTAs (online travel agencies), and tour operators to offer airport transfers and ground transportation services to their customers without building their own supply network. Founded in 2019 and based in Cancun, Mexico, Shuttle Central raised $5.59 million from Y Combinator, Goodwater Capital, 500 Global, and Gaingels — connecting transportation providers in tourist-heavy markets to travel platforms via API integration.\n\nShuttle Central's platform allows travel companies to embed ground transportation bookings (airport transfers, hotel shuttles, city tours) directly into their checkout flows via API, earning a commission on each booking without managing transportation logistics. For hotels, tour operators, and booking platforms, offering transportation at the point of hotel or excursion booking converts at higher rates than post-booking upsells. Shuttle Central's supplier network covers airports and tourist destinations across Latin America and the Caribbean, with Cancun as a key initial market given its concentration of international tourist arrivals.\n\nIn 2025, Shuttle Central operates in the ground transportation and transfer booking market alongside Viator (TripAdvisor), GetTransfer, and Mozio for travel transfer marketplace solutions. The travel industry rebound post-COVID has driven strong demand for seamlessly integrated transportation options, as travelers increasingly book full itineraries through single platforms rather than booking each element separately. Shuttle Central's API-first model positions it as infrastructure for travel businesses rather than a consumer-facing booking site. The 2025 strategy focuses on expanding supply coverage to more tourist destinations, deepening integrations with larger OTAs, and growing beyond Latin America into European and Asian tourism markets.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.